PF-Atlas › Clinical Trials › NCT02690519
Study of GLPG1837 in Subjects With Cystic Fibrosis
GLPG1837 dose 1 · Phase 2
Registry ID
NCT02690519
Phase
Phase 2
Status
Completed
Drug / intervention
GLPG1837 dose 1
Sponsor
Lakefront Biotherapeutics NV
Start
2016-01
About this trial
GLPG1837 dose 1 is evaluated in NCT02690519, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Lakefront Biotherapeutics NV. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02690519 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.